Neonc Technologies Holdings, Inc.
NTHIHealthcare|Biotechnology|US
$3.49
+0.29 (+9.06%)
Cash / Share
$0.24
Clinical Trials (4)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05023018 NEO100 and High-Grade Meningioma | Residual, Progressive or Recurrent Grade II or III Meningioma | P2 | Recruiting | 30 | Open-label | NEO100 |
| NCT06047379 Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype | P1P2 | Recruiting | 134 | Open-label | NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab |
| NCT02704858 Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma | Glioblastoma Multiforme | P1P2 | Active | 49 | Open-label | Perillyl alcohol |
| NCT06357377 A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors | Pediatric Tumor of CNS, Pediatric Tumor of Brain | P1 | Recruiting | 12 | Open-label | NEO100 |